Cargando…
Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study
OBJECTIVE: To estimate the effectiveness of the three covid-19 vaccines by Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), and Oxford-AstraZeneca (ChAdOx1-S) in people after receiving two doses. DESIGN: Cohort study. SETTING: Nationwide, population based data in France, from the French National Hea...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978755/ https://www.ncbi.nlm.nih.gov/pubmed/36936561 http://dx.doi.org/10.1136/bmjmed-2021-000104 |
_version_ | 1784899586521825280 |
---|---|
author | Bouillon, Kim Baricault, Bérangère Botton, Jérémie Jabagi, Marie-Joëlle Bertrand, Marion Semenzato, Laura Le Vu, Stéphane Drouin, Jérôme Dray-Spira, Rosemary Weill, Alain Zureik, Mahmoud |
author_facet | Bouillon, Kim Baricault, Bérangère Botton, Jérémie Jabagi, Marie-Joëlle Bertrand, Marion Semenzato, Laura Le Vu, Stéphane Drouin, Jérôme Dray-Spira, Rosemary Weill, Alain Zureik, Mahmoud |
author_sort | Bouillon, Kim |
collection | PubMed |
description | OBJECTIVE: To estimate the effectiveness of the three covid-19 vaccines by Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), and Oxford-AstraZeneca (ChAdOx1-S) in people after receiving two doses. DESIGN: Cohort study. SETTING: Nationwide, population based data in France, from the French National Health Data System (Système National des Données de Santé), between 27 December 2020 and 30 April 2021. PARTICIPANTS: Adults aged ≥50 years receiving a first dose of BNT162b2, mRNA-1273, or ChAdOx1-S were randomly selected (1:1) and matched on the date of vaccination with one unvaccinated control. Individuals were matched on year of birth, sex, region of residence, and residence in a nursing home (for individuals aged ≥75 years). All individuals were followed up until 20 August 2021. MAIN OUTCOME MEASURES: Primary outcome measure was vaccine effectiveness estimated at least 14 days after the second dose against covid-19 related hospital admission using Cox proportional hazards models adjusted for baseline characteristics and comorbidities. Vaccine effectiveness against covid-19 related death in hospital was also investigated. RESULTS: 11 256 832 vaccinated individuals were included in the study (63.6% (n=7 161 658) with the BNT162b2 vaccine, 7.6% (n=856 599) with the mRNA-1273 vaccine, and 28.8% (n=3 238 575) with the ChAdOx1-S vaccine), along with 11 256 832 matched unvaccinated controls. During follow-up (up to 20 August 2021), 43 158 covid-19 related hospital admissions and 7957 covid-19 related deaths in hospital were registered. Compared with unvaccinated controls, vaccine effectiveness of two doses against covid-19 related hospital admission was 91% (95% confidence interval 91% to 92%), 95% (93% to 96%), and 91% (89% to 94%) for the BNT162b2, mRNA-1273, and ChAdOx1-S vaccines, respectively. Similar results were observed for vaccine effectiveness of two doses against covid-19 related deaths in hospital (BNT162b2, 91% (90% to 93%); mRNA-1273, 96% (92% to 98%); and ChAdOx1 nCoV-19, 88% (68% to 95%)). At 5-6 months after receiving the second dose of vaccine, effectiveness remained high at 94% (92% to 95%) for the BNT162b2 vaccine and 98% (93% to 100%) for the mRNA-1273 vaccine. Vaccine effectiveness of ChAdOx1-S estimated at 3-4 months was 90% (63% to 97%). All three vaccines remained effective at the time of circulation of the delta variant of SARS-CoV-2 between 1 July and 20 August 2021 (effectiveness between 89% and 95%). CONCLUSIONS: These findings provide evidence indicating that two doses of ChAdOx1-S is as effective as two doses of mRNA vaccines in France against the alpha and delta variants of SARS-CoV-2. The effectiveness of ChAdOx1-S should be further examined with a longer follow-up and in the light of the circulation of new SARS-CoV-2 variants of concern. |
format | Online Article Text |
id | pubmed-9978755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-99787552023-03-16 Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study Bouillon, Kim Baricault, Bérangère Botton, Jérémie Jabagi, Marie-Joëlle Bertrand, Marion Semenzato, Laura Le Vu, Stéphane Drouin, Jérôme Dray-Spira, Rosemary Weill, Alain Zureik, Mahmoud BMJ Med Research OBJECTIVE: To estimate the effectiveness of the three covid-19 vaccines by Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), and Oxford-AstraZeneca (ChAdOx1-S) in people after receiving two doses. DESIGN: Cohort study. SETTING: Nationwide, population based data in France, from the French National Health Data System (Système National des Données de Santé), between 27 December 2020 and 30 April 2021. PARTICIPANTS: Adults aged ≥50 years receiving a first dose of BNT162b2, mRNA-1273, or ChAdOx1-S were randomly selected (1:1) and matched on the date of vaccination with one unvaccinated control. Individuals were matched on year of birth, sex, region of residence, and residence in a nursing home (for individuals aged ≥75 years). All individuals were followed up until 20 August 2021. MAIN OUTCOME MEASURES: Primary outcome measure was vaccine effectiveness estimated at least 14 days after the second dose against covid-19 related hospital admission using Cox proportional hazards models adjusted for baseline characteristics and comorbidities. Vaccine effectiveness against covid-19 related death in hospital was also investigated. RESULTS: 11 256 832 vaccinated individuals were included in the study (63.6% (n=7 161 658) with the BNT162b2 vaccine, 7.6% (n=856 599) with the mRNA-1273 vaccine, and 28.8% (n=3 238 575) with the ChAdOx1-S vaccine), along with 11 256 832 matched unvaccinated controls. During follow-up (up to 20 August 2021), 43 158 covid-19 related hospital admissions and 7957 covid-19 related deaths in hospital were registered. Compared with unvaccinated controls, vaccine effectiveness of two doses against covid-19 related hospital admission was 91% (95% confidence interval 91% to 92%), 95% (93% to 96%), and 91% (89% to 94%) for the BNT162b2, mRNA-1273, and ChAdOx1-S vaccines, respectively. Similar results were observed for vaccine effectiveness of two doses against covid-19 related deaths in hospital (BNT162b2, 91% (90% to 93%); mRNA-1273, 96% (92% to 98%); and ChAdOx1 nCoV-19, 88% (68% to 95%)). At 5-6 months after receiving the second dose of vaccine, effectiveness remained high at 94% (92% to 95%) for the BNT162b2 vaccine and 98% (93% to 100%) for the mRNA-1273 vaccine. Vaccine effectiveness of ChAdOx1-S estimated at 3-4 months was 90% (63% to 97%). All three vaccines remained effective at the time of circulation of the delta variant of SARS-CoV-2 between 1 July and 20 August 2021 (effectiveness between 89% and 95%). CONCLUSIONS: These findings provide evidence indicating that two doses of ChAdOx1-S is as effective as two doses of mRNA vaccines in France against the alpha and delta variants of SARS-CoV-2. The effectiveness of ChAdOx1-S should be further examined with a longer follow-up and in the light of the circulation of new SARS-CoV-2 variants of concern. BMJ Publishing Group 2022-06-13 /pmc/articles/PMC9978755/ /pubmed/36936561 http://dx.doi.org/10.1136/bmjmed-2021-000104 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Research Bouillon, Kim Baricault, Bérangère Botton, Jérémie Jabagi, Marie-Joëlle Bertrand, Marion Semenzato, Laura Le Vu, Stéphane Drouin, Jérôme Dray-Spira, Rosemary Weill, Alain Zureik, Mahmoud Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study |
title | Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study |
title_full | Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study |
title_fullStr | Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study |
title_full_unstemmed | Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study |
title_short | Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study |
title_sort | effectiveness of bnt162b2, mrna-1273, and chadox1-s vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978755/ https://www.ncbi.nlm.nih.gov/pubmed/36936561 http://dx.doi.org/10.1136/bmjmed-2021-000104 |
work_keys_str_mv | AT bouillonkim effectivenessofbnt162b2mrna1273andchadox1svaccinesagainstseverecovid19outcomesinanationwidemassvaccinationsettingcohortstudy AT baricaultberangere effectivenessofbnt162b2mrna1273andchadox1svaccinesagainstseverecovid19outcomesinanationwidemassvaccinationsettingcohortstudy AT bottonjeremie effectivenessofbnt162b2mrna1273andchadox1svaccinesagainstseverecovid19outcomesinanationwidemassvaccinationsettingcohortstudy AT jabagimariejoelle effectivenessofbnt162b2mrna1273andchadox1svaccinesagainstseverecovid19outcomesinanationwidemassvaccinationsettingcohortstudy AT bertrandmarion effectivenessofbnt162b2mrna1273andchadox1svaccinesagainstseverecovid19outcomesinanationwidemassvaccinationsettingcohortstudy AT semenzatolaura effectivenessofbnt162b2mrna1273andchadox1svaccinesagainstseverecovid19outcomesinanationwidemassvaccinationsettingcohortstudy AT levustephane effectivenessofbnt162b2mrna1273andchadox1svaccinesagainstseverecovid19outcomesinanationwidemassvaccinationsettingcohortstudy AT drouinjerome effectivenessofbnt162b2mrna1273andchadox1svaccinesagainstseverecovid19outcomesinanationwidemassvaccinationsettingcohortstudy AT drayspirarosemary effectivenessofbnt162b2mrna1273andchadox1svaccinesagainstseverecovid19outcomesinanationwidemassvaccinationsettingcohortstudy AT weillalain effectivenessofbnt162b2mrna1273andchadox1svaccinesagainstseverecovid19outcomesinanationwidemassvaccinationsettingcohortstudy AT zureikmahmoud effectivenessofbnt162b2mrna1273andchadox1svaccinesagainstseverecovid19outcomesinanationwidemassvaccinationsettingcohortstudy |